← Back to Analyst Consensus 
PYXS Buy
Pyxis Oncology, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 17, 2026 (21 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 10, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Sep 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 9, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Aug 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 3, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Jul 2, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| May 5, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| Mar 24, 2026 | Stifel | maintain | Buy → Buy | — | 54% |
| Mar 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Dec 19, 2025 | RBC Capital | maintain | Outperform → Outperform | $5 | 55% |
| Dec 19, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Nov 24, 2025 | Stephens & Co. | maintain | Overweight → Overweight | $8 | 54% |
| Nov 4, 2025 | Guggenheim | maintain | Buy → Buy | $7 | 52% |
| Sep 4, 2025 | Guggenheim | initiate | — → Buy | $5 | 52% |
| Aug 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| May 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Mar 19, 2025 | RBC Capital | reiterate | Outperform → Outperform | $8 | 55% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Dec 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Dec 20, 2024 | RBC Capital | reiterate | Outperform → Outperform | $8 | 55% |
| Nov 21, 2024 | RBC Capital | maintain | Outperform → Outperform | $10 | 55% |
| Nov 21, 2024 | William Blair | downgrade | Outperform → Market Perform | $0 | 48% |
| Nov 21, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Nov 8, 2024 | Stephens & Co. | initiate | — → Overweight | $13 | 54% |
| Sep 19, 2024 | RBC Capital | reiterate | Outperform → Outperform | $7 | 55% |
| Aug 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Aug 8, 2024 | Stifel | initiate | — → Buy | $10 | 54% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Apr 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Mar 22, 2024 | RBC Capital | reiterate | Outperform → Outperform | $7 | 55% |
| Mar 22, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Feb 9, 2024 | BTIG | initiate | — → Buy | $8 | 52% |
| Jan 23, 2024 | Leerink Partners | initiate | — → Outperform | $12 | 51% |
| Nov 30, 2023 | HC Wainwright & Co. | initiate | — → Buy | $4 | 44% |
| Sep 5, 2023 | RBC Capital | initiate | — → Outperform | $7 | 55% |
| Jul 31, 2023 | EF Hutton | initiate | — → Buy | $15 | 30% |
| Mar 23, 2023 | Credit Suisse | reiterate | — → Outperform | $14 | — |
| Nov 2, 2021 | B of A Securities | initiate | — → Neutral | $16 | 53% |
| Nov 2, 2021 | Jefferies | initiate | — → Buy | $25 | 52% |
| Nov 2, 2021 | Credit Suisse | initiate | — → Outperform | $19 | — |
Price Target Trend
May 4, 2026 Oct 26, 2026
EPS Estimates
+1y —
0y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days